Form: 424B3

Prospectus filed pursuant to Rule 424(b)(3)

August 10, 2022


Filed pursuant to Rule 424(b)(3) 
Registration Statement No. 333-258748
Prospectus Supplement No. 5
(To Prospectus dated April 27, 2022)
This prospectus supplement updates, amends and supplements the prospectus dated April 27, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-258748). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.
This prospectus supplement is being filed to update, amend and supplement the information included in the Prospectus with information on Evolv Technologies Holdings, Inc.’s unaudited second quarter 2022 financial results, which is set forth below.
This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.
Our Class A common stock is quoted on The Nasdaq Stock Market, or NASDAQ, under the symbol “EVLV” and our warrants are quoted on the NASDAQ under the symbol “EVLVW.” On August 10, 2022, as reported on NASDAQ, the closing sale price of our Class A common stock was $3.00 and the closing sale price of our warrants was $0.47.
We are an “emerging growth company” under federal securities laws and are subject to reduced public company reporting requirements. Investing in our securities involves certain risks. See “Risk Factors” beginning on page 3 of the Prospectus.
Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is August 10, 2022.



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 10, 2022
Evolv Technologies Holdings, Inc.
(Exact name of registrant as specified in its charter)
Delaware 001-39417 84-4473840
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
500 Totten Pond Road, 4th Floor
Waltham, Massachusetts
02451
(Address of principal executive offices) (Zip Code)
(781) 374-8100
Registrant’s telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which
registered
Class A common stock, par value $0.0001 per share EVLV The Nasdaq Stock Market
Warrants to purchase one share of Class A common stock EVLVW The Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 



Item 2.02    Results of Operations and Financial Condition.
On August 10, 2022, Evolv Technologies Holdings, Inc. (the “Company”) announced financial results for the three and six months ended June 30, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01    Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Evolv Technologies Holdings, Inc.
Date: August 10, 2022 By: /s/ Peter George
Name: Peter George
Title: Chief Executive Officer

 

Exhibit 99.1
image_0a.jpg
Investor Relations:
Brian Norris
Vice President of Finance and Investor Relations
bnorris@evolvtechnology.com
Evolv Technology Reports Strong Second Quarter Financial Results
– Company Reaffirms Outlook for 2022 

Q2 Revenue of $9.1 million, up 94% year-over-year
Q2 Ending ARR of $20.9 million, up 181% year-over-year
Q2 Ending RPO of $66.2 million, up 166% year-over-year
Q2 Ending Evolv Express® subscriptions of 1,147, up 193% year-over-year
Waltham, Massachusetts – August 10, 2022 – Evolv Technology (NASDAQ: EVLV), a global leader in weapons detection security screening, today announced financial results for its second quarter ended June 30, 20221 and reaffirmed its business outlook for 2022.

“We are pleased to be reporting strong second quarter results highlighted by the addition of over 50 new customers, continued expansion in our key vertical and geographic markets and important traction with our key channel partners,” said Peter George, President and Chief Executive Officer of Evolv Technology. “We’re particularly pleased to have surpassed 1,100 Evolv Express systems deployed and $100 million in cumulative TCV bookings this quarter. Based on the strength of our first half results and our growing market momentum, we remain confident in our full year growth plans for 2022.”

Results for the Second Quarter of 2022
Total revenue for the second quarter of 2022 was $9.1 million, an increase of 94% compared to $4.7 million for the second quarter of 2021. Total Contract Value (“TCV”)2 of orders booked for the second quarter of 2022 was $22.1 million, an increase of 111% compared to $10.5 million in the second quarter of 2021. Annual Recurring Revenue (“ARR”)3 was $20.9 million at the end of second quarter of 2022, an increase of 181% compared to $7.4 million at the end of the second quarter of 2021. Net loss for the second quarter of 2022 was $(25.7) million, or $(0.18) per basic and diluted share, compared to net loss of $(23.0) million, or $(1.93) per basic and diluted share, in the second quarter of 2021. Adjusted earnings (loss)4 for the second quarter of 2022 was $(17.3) million, or $(0.12) per basic and diluted share, compared to $(9.1) million, or $(0.76) per basic and diluted share, for the second quarter of 2021. Adjusted EBITDA4 for the second quarter of 2022 was $(16.4) million compared to $(5.2) million in the second quarter of 2021. As of June 30, 2022, the Company had cash and cash equivalents of $242.7 million compared to $270.9 million as of March 31, 2022.

Results for the First Six Months of 2022
Total revenue for the six months ended June 30, 2022 was $17.8 million, an increase of 112% compared to $8.4 million for the six months ended June 30, 2021. TCV2 of orders booked for the six months ended June 30, 2022 was $41.2 million, an increase of 118% compared to $18.9 million in the six months ended June 30, 2021. Net loss for the six months ended June 30, 2022 was $(39.5) million, or $(0.28) per basic and diluted share, compared to net loss of $(36.5) million, or $(3.26) per basic and diluted share, for the six months ended June 30, 2021. Adjusted earnings (loss)4 for the six months ended June 30, 2022 was $(35.8) million, or $(0.25) per basic and diluted share, compared to $(20.1) million, or $(1.80) per basic and



diluted share, for the six months ended June 30, 2021. Adjusted EBITDA4 for the six months ended June 30, 2022 was $(33.7) million, compared to $(13.4) million for the six months ended June 30, 2021.
Company Reaffirms Outlook for 2022
The Company today commented on its business outlook for 2022. The Company's outlook is based on the current indications for its business, which may change at any time.
2022 Business Outlook
Estimate (In millions)
Issued May 11, 2022
Issued August 10, 2022
Total Revenue $29-$31 No change
Annual Recurring Revenue3 (ARR) at 12/31
$27-$28 No change
Adjusted EBITDA4
($65-$67) No change
Cash and Cash Equivalents $220-$230 No change

Company to Host Live Conference Call and Webcast
The Company’s management team plans to host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss the financial results as well as management’s outlook for the business and other matters. The conference call may be accessed in the United States by dialing +1.877.692.8955 and using access code 774298. The conference call may be accessed outside of the United States by dialing +1.234.720.6979 and using the same access code. The conference call will be simultaneously webcast on the Company’s investor relations website, which can be accessed at http://ir.evolvtechnology.com. A replay of the conference call will be available for a period of 30 days by dialing +1.866.207.1041 or +1.402.970.0847 and using access code 7860978 or by accessing the webcast replay on the Company’s investor relations website at http://ir.evolvtechnology.com.
About Evolv Technology
Evolv Technology (NASDAQ: EVLV) is transforming human security to make a safer, faster, and better experience for the world’s most iconic venues and companies as well as schools, hospitals, and public spaces, using industry leading artificial intelligence (AI)-powered weapons detection and analytics.  Its mission is to transform security to create a safer world to work, learn, and play. Evolv has digitally transformed the gateways in places where people gather by enabling seamless integration combined with powerful analytics and insights. Evolv’s advanced systems have scanned more than 350 million people, second only to the Department of Homeland Security’s Transportation Security Administration (TSA) in the United States.  Evolv has been awarded the U.S. Department of Homeland Security (DHS) SAFETY Act Designation as a Qualified Anti-Terrorism Technology (QATT) as well as the Security Industry Association (SIA) New Products and Solutions (NPS) Award in the Law Enforcement/Public Safety/Guarding Systems category. For more information, visit https://evolvtechnology.com.
1 Amounts herein pertaining to June 30, 2022 represent a preliminary estimate as of the date of this earnings release. More information on our results of operations for the three and six months ended June 30, 2022 will be provided upon filing our Quarterly Report on Form 10-Q with the Securities and Exchange Commission.

2 We define Total Contract Value, or TCV, of orders booked as the total value of the contract over the specified term. Our calculation of TCV is not adjusted for the impact of any known or projected future events (such as customer cancellations, upgrades or downgrades, or price increases or decreases). TCV should be viewed independently of, and not as a substitute for or forecast of, revenue and deferred revenue. Our calculation of TCV may differ from similarly titled metrics presented by other companies.
3 We define Annual Recurring Revenue, or ARR, as subscription revenue and the recurring service revenue related to purchase subscriptions for the final month of the quarter normalized to a one-year period. Our calculation of ARR is not adjusted for the impact of any known or projected future events (such as customer cancellations, upgrades or downgrades, or price increases or decreases) that may cause any such contract not to be renewed on its existing terms. In addition, the amount of actual revenue that we recognize over any 12-month period is likely to differ from ARR at the beginning of that period, sometimes significantly. This may occur due to new bookings, cancellations, upgrades, downgrades or other changes in pending renewals, as well as the effects of professional services revenue and acquisitions or divestitures. As a result, ARR should be viewed independently of, and not as a substitute for or forecast of, revenue and deferred revenue. Our calculation of ARR may differ from similarly titled metrics presented by other companies.



4 Non-GAAP Financial Measures In this press release, the Company’s adjusted gross profit, adjusted gross margin, adjusted EBITDA, adjusted earnings (loss) and adjusted earnings per share are not presented in accordance with generally accepted accounting principles (GAAP) and are not intended to be used in lieu of GAAP presentations of results of operations. Adjusted gross profit and adjusted gross margin exclude one-time items which management believes provides a more meaningful representation of contribution margin. Adjusted EBITDA is defined as net income (loss) plus depreciation and amortization, share-based compensation, and certain other one-time expenses. Adjusted earnings (loss) is defined as net income (loss) plus stock-based compensation, change in fair value of derivative liability, change in fair value of contingent earn-out liability, change in fair value of contingently issuable common stock liability, change in fair value of public warrant liability, change in fair value of common stock warrant liability, restructuring expenses, loss on impairment of lease equipment, and certain other one-time expenses. Management presents non-GAAP financial measures because it considers them to be important supplemental measures of performance. Management uses non-GAAP financial measures for planning purposes, including analysis of the Company's performance against prior periods, the preparation of operating budgets and to determine appropriate levels of operating and capital investments. Management also believes non-GAAP financial measures provide additional insight for analysts and investors in evaluating the Company's financial and operational performance. However, non-GAAP financial measures have limitations as an analytical tool and are not intended to be an alternative to financial measures prepared in accordance with GAAP. We intend to provide non-GAAP financial measures as part of our future earnings discussions and, therefore, the inclusion of non-GAAP financial measures will provide consistency in our financial reporting. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures included in this press release.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking” statements and information, within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 that relate to our current expectations and views of future events including but not limited to statements regarding our ability to meet our business outlook for revenue and profitability. Forward-looking statements involve the Company’s current expectations and projections relating to its financial condition, competitive position, future financial results, plans, objectives, and business. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, these forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “should,” “could,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or the negative of these terms or other similar expressions. These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect the Company’s current views with respect to future events and the Company’s performance and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation expectations regarding the Company’s strategies and future financial performance, including its future business plans or objectives, prospective performance and opportunities and competitors, revenues, products and services, pricing, operating expenses, market trends, liquidity, cash flows and uses of cash, capital expenditures; the Company’s history of losses and lack of profitability; the Company’s reliance on third party contract manufacturing; the rate of innovation required to maintain competitiveness in the markets in which the Company competes; the competitiveness of the market in which the Company competes; the ability for the Company to obtain, maintain, protect and enforce the Company’s intellectual property rights; the concentration of the Company’s revenues on a single solution; the Company’s ability to timely design, produce and launch its solutions, the Company’s ability to invest in growth initiatives and pursue acquisition opportunities; the limited liquidity and trading of the Company’s securities; geopolitical risk and changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; operational risk; risk that the COVID-19 pandemic, including variants, vaccine roll-out efforts, and local, state, and federal responses to addressing the pandemic may have an adverse effect on the Company’s business operations, as well as the Company’s financial condition and results of operations; risks associated with inflation and its possible impact on the Company; litigation and regulatory enforcement risks, including the diversion of management time and attention and the additional costs and demands on resources; and the risk factors set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission ("SEC") on March 28, 2022 as may be updated in other filings we make with the SEC.
These statements reflect management’s current expectations regarding future events and operating performance and speak only as of the date of this press release. You should not put undue reliance on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.



EVOLV TECHNOLOGY
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share data)
(Unaudited)
Three Months Ended
June 30,
Six Months Ended
June 30,
2022 2021 2022 2021
Revenue:
Product revenue $ 4,146  $ 2,617  $ 9,340  $ 4,884 
Subscription revenue 4,006  1,521  7,010  2,748 
Service revenue 918  540  1,430  739 
Total revenue 9,070  4,678  17,780  8,371 
Cost of revenue:
Cost of product revenue 5,347  2,203  10,553  4,419 
Cost of subscription revenue 1,981  1,060  3,523  1,803 
Cost of service revenue 1,189  687  2,254  972 
Total cost of revenue 8,517  3,950  16,330  7,194 
Gross profit 553  728  1,450  1,177 
Operating expenses:
Research and development 4,156  1,047  8,331  4,787 
Sales and marketing 11,751  5,124  21,423  7,732 
General and administrative 9,612  1,471  20,429  4,523 
Loss from impairment of property and equipment 316  —  412  — 
Total operating expenses 25,835  7,642  50,595  17,042 
Loss from operations (25,282) (6,914) (49,145) (15,865)
Other income (expense), net:
Interest expense (159) (3,263) (301) (5,657)
Interest income 491  —  559  — 
Loss on extinguishment of debt —  (11,820) —  (11,820)
Change in fair value of derivative liability —  (795) —  (2,220)
Change in fair value of contingent earn-out liability (569) —  2,509  — 
Change in fair value of contingently issuable common stock liability (24) —  1,448  — 
Change in fair value of public warrant liability (143) —  5,443  — 
Change in fair value of common stock warrant liability —  (185) —  (921)
Total other income (expense), net (404) (16,063) 9,658  (20,618)
Net loss $ (25,686) $ (22,977) $ (39,487) $ (36,483)
Weighted average common shares outstanding - basic and diluted 143,552,032 11,922,270 143,220,268 11,186,204
Net loss per share - basic and diluted $ (0.18) $ (1.93) $ (0.28) $ (3.26)
Net loss $ (25,686) $ (22,977) $ (39,487) $ (36,483)
Other comprehensive loss
Cumulative translation adjustment (10) —  (10) — 
Total other comprehensive loss (10) —  (10) — 
Total comprehensive loss $ (25,696) $ (22,977) $ (39,497) $ (36,483)



EVOLV TECHNOLOGY
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
(Unaudited)
June 30, 2022 December 31, 2021
Assets
Current assets:
Cash and cash equivalents $ 242,691  $ 307,492 
Restricted cash 400  400 
Accounts receivable, net 12,183  6,477 
Inventory 6,010  2,890 
Current portion of contract assets 6,180  1,459 
Current portion of commission asset 2,079  1,645 
Prepaid expenses and other current assets 20,920  10,757 
Total current assets 290,463  331,120 
Restricted cash, noncurrent 275  275 
Contract assets, noncurrent 3,159  3,418 
Commission asset, noncurrent 3,624  3,719 
Property and equipment, net 34,379  23,783 
Operating lease right-of-use assets 2,092  — 
Other assets 2,172  542 
Total assets $ 336,164  $ 362,857 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable $ 9,427  $ 6,045 
Accrued expenses and other current liabilities 7,759  9,551 
Current portion of deferred revenue 13,892  6,599 
Current portion of deferred rent —  135 
Current portion of long-term debt 4,000  2,000 
Current portion of operating lease liabilities 1,097  — 
Total current liabilities 36,175  24,330 
Deferred revenue, noncurrent 4,330  2,475 
Deferred rent, noncurrent —  333 
Long-term debt, noncurrent 5,955  7,945 
Operating lease liabilities, noncurrent 1,398  — 
Contingent earn-out liability 18,697  21,206 
Contingently issuable common stock liability 3,816  5,264 
Public warrant liability 5,587  11,030 
Total liabilities 75,958  72,583 
Stockholders’ equity:
Preferred stock, $0.0001 par value; 100,000,000 authorized at June 30, 2022 and December 31, 2021; no shares issued and outstanding at June 30, 2022 and December 31, 2021 —  — 
Common stock, $0.0001 par value; 1,100,000,000 shares authorized at June 30, 2022 and December 31, 2021; 143,829,995 and 142,745,021 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively 14  14 
Additional paid-in capital 405,493  396,064 
Accumulated other comprehensive loss (10) — 
Accumulated deficit (145,291) (105,804)
Stockholders’ equity 260,206  290,274 
Total liabilities and stockholders’ equity $ 336,164  $ 362,857 




EVOLV TECHNOLOGY
REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS
(In thousands)
(Unaudited)

In preparing the condensed consolidated financial statements as of and for the three and six months ended June 30, 2022, the Company identified various errors in its previously issued financial statements. The identified errors impacted the Company's previously issued 2021 quarterly and annual financial statements and its quarterly financial statements for the three months ended March 31, 2022, and accordingly the Company has made adjustments to the prior period amounts presented herein. A summary of the revisions to certain previously reported financial information impacting amounts presented in this earnings release is as follows (in thousands):

Three Months Ended
June 30, 2021
Six Months Ended
June 30, 2021
As Previously Reported Adjustment Revised As Previously Reported Adjustment Revised
Revenue:
Product revenue $ 2,452  $ 165  $ 2,617  $ 4,954  $ (70) $ 4,884 
Subscription revenue 1,513  1,521  2,813  (65) 2,748 
Service revenue 515  25  540  712  27  739 
Total revenue 4,480  198  4,678  8,479  (108) 8,371 
Cost of revenue:
Cost of product revenue 2,075  128  2,203  4,304  115  4,419 
Cost of subscription revenue 861  199  1,060  1,456  347  1,803 
Cost of service revenue 413  274  687  540  432  972 
Total cost of revenue 3,349  601  3,950  6,300  894  7,194 
Gross profit 1,131  (403) 728  2,179  (1,002) 1,177 
Operating expenses:
Research and development 1,077  (30) 1,047  4,689  98  4,787 
Sales and marketing expense 5,090  34  5,124  8,774  (1,042) 7,732 
General and administrative 1,280  191  1,471  4,179  344  4,523 
Loss from impairment of property and equipment —  —  —  —  —  — 
Total operating expenses 7,447  195  7,642  17,642  (600) 17,042 
Loss from operations (6,316) (598) (6,914) (15,463) (402) (15,865)
Other income (expense), net:
Interest expense (3,255) (8) (3,263) (5,702) 45  (5,657)
Interest income —  —  —  —  —  — 
Loss on extinguishment of debt (11,820) —  (11,820) (11,820) —  (11,820)
Change in fair value of derivative liability (795) —  (795) (2,220) —  (2,220)
Change in fair value of contingent earn-out liability —  —  —  —  —  — 
Change in fair value of contingently issuable common stock liability —  —  —  —  —  — 
Change in fair value of public warrant liability —  —  —  —  —  — 
Change in fair value of common stock warrant liability (185) —  (185) (921) —  (921)
Total other income (expense), net (16,055) (8) (16,063) (20,663) 45  (20,618)
Net loss $ (22,371) $ (606) $ (22,977) $ (36,126) $ (357) $ (36,483)




December 31, 2021
As Previously Reported Adjustment Revised
Assets
Current assets:
Cash and cash equivalents $ 307,492  $ —  $ 307,492 
Restricted cash 400  —  400 
Accounts receivable, net 6,477  —  6,477 
Inventory 5,140  (2,250) 2,890 
Current portion of contract assets 1,459  —  1,459 
Current portion of commission asset 1,645  —  1,645 
Prepaid expenses and other current assets 11,047  (290) 10,757 
Total current assets 333,660  (2,540) 331,120 
Restricted cash, noncurrent 275  —  275 
Contract assets, noncurrent 3,418  —  3,418 
Commission asset, noncurrent 3,719  —  3,719 
Property and equipment, net 21,592  2,191  23,783 
Operating lease right-of-use assets —  —  — 
Other assets 401  141  542 
Total assets $ 363,065  $ (208) $ 362,857 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable $ 6,363  $ (318) $ 6,045 
Accrued expenses and other current liabilities 9,183  368  9,551 
Current portion of deferred revenue 6,690  (91) 6,599 
Current portion of deferred rent 135  —  135 
Current portion of long-term debt 2,000  —  2,000 
Current portion of operating lease liabilities —  —  — 
Total current liabilities 24,371  (41) 24,330 
Deferred revenue, noncurrent 2,475  —  2,475 
Deferred rent, noncurrent 333  —  333 
Long-term debt, noncurrent 7,945  —  7,945 
Operating lease liabilities, noncurrent —  —  — 
Contingent earn-out liability 20,809  397  21,206 
Contingently issuable common stock liability 5,264  —  5,264 
Public warrant liability 11,030  —  11,030 
Total liabilities 72,227  356  72,583 
Stockholders’ equity:
Preferred stock, $0.0001 par value; 100,000,000 authorized at December 31, 2021; no shares issued and outstanding at December 31, 2021 —  —  — 
Common stock, $0.0001 par value; 1,100,000,000 shares authorized at December 31, 2021; 142,745,021 shares issued and outstanding at December 31, 2021 14  —  14 
Additional paid-in capital 395,563  501  396,064 
Accumulated other comprehensive loss —  —  — 
Accumulated deficit (104,739) (1,065) (105,804)
Stockholders’ equity 290,838  (564) 290,274 
Total liabilities and stockholders’ equity $ 363,065  $ (208) $ 362,857 



EVOLV TECHNOLOGY
RECONCILIATION OF FORECASTED 2022 NET LOSS TO ADJUSTED EBITDA
(In thousands)
(Unaudited)
Twelve Months Ended
December 31, 2022
High Low
Net income (loss) $ (81,000) $ (83,000)
Adjustments to reconcile net income (loss) to Adjusted EBITDA:
Depreciation and amortization 6,000  6,000 
Stock-based compensation 17,000  17,000 
Other one-time expenses 5,000  5,000 
Other (income) expense (12,000) (12,000)
Adjusted EBITDA $ (65,000) $ (67,000)
EVOLV TECHNOLOGY
SUMMARY OF KEY OPERATING STATISTICS
(Unaudited)
Three Months Ended,
($ in thousands) March 31,
2021
June 30,
2021
September 30,
2021
December 31,
2021
March 31,
2022
June 30,
2022
New customers 13  21  23  27  44  53 
Total contract value of orders booked $ 8,424  $ 10,476  $ 16,995  $ 17,916  $ 19,167  $ 22,066 
Annual recurring revenue $ 5,424  $ 7,423  $ 9,932  $ 12,907  $ 16,641  $ 20,865 
Remaining performance obligation $ 17,658  $ 24,930  $ 34,152  $ 40,160  $ 50,537  $ 66,238 
Contract value for units in backlog n/a n/a n/a $ 11,270  $ 13,213  $ 14,740 
Net additions 64  113  176  136  207  237 
Ending deployed units 278  391  567  703  910  1,147 

EVOLV TECHNOLOGY
RECONCILIATION OF GAAP OPERATING EXPENSES TO ADJUSTED OPERATING EXPENSES
(In thousands)
(Unaudited)

Three Months Ended,
March 31,
2021
June 30,
2021
September 30,
2021
December 31,
2021
March 31,
2022
June 30,
2022
Operating expenses, GAAP $ 9,400  $ 7,642  $ 22,826  $ 19,429  $ 24,760  $ 25,835 
Stock-based compensation (304) (1,062) (4,626) (3,546) (3,867) (5,010)
Restructuring expenses —  —  —  —  (324) 14 
Loss on impairment of lease equipment —  —  (1,656) (213) (96) (316)
Other one-time expenses —  —  (685) —  (1,107) (2,298)
Adjusted Operating Expenses $ 9,096  $ 6,580  $ 15,859  $ 15,670  $ 19,366  $ 18,225 



EVOLV TECHNOLOGY
RECONCILIATION OF GAAP GROSS PROFIT TO ADJUSTED GROSS PROFIT AND GAAP OPERATING INCOME (LOSS) TO ADJUSTED OPERATING INCOME (LOSS)
(In thousands)
(Unaudited)
Three Months Ended
June 30,
Six Months Ended
June 30,
2022 2021 2022 2021
Revenue $ 9,070  $ 4,678  $ 17,780  $ 8,371 
Cost of revenue 8,517  3,950  16,330  7,194 
Gross Profit, GAAP 553  728  1,450  1,177 
Stock-based compensation 52  112  10 
Amortization of capitalized stock-based compensation —  — 
Adjusted Gross Profit $ 610  $ 733  $ 1,571  $ 1,187 
Gross Margin % 6.1  % 15.6  % 8.2  % 14.1  %
Adjusted Gross Margin % 6.7  % 15.7  % 8.8  % 14.2  %
Three Months Ended
June 30,
Six Months Ended
June 30,
2022 2021 2022 2021
Operating income (loss), GAAP $ (25,282) $ (6,914) $ (49,145) $ (15,865)
Stock-based compensation 5,061  1,069  8,988  1,376 
Amortization of capitalized stock-based compensation —  — 
Restructuring expenses (13) —  311  — 
Loss on impairment of lease equipment 316  —  412  — 
Other one-time expenses 2,298  —  3,405  — 
Adjusted Operating Income (loss) $ (17,615) $ (5,845) $ (36,020) $ (14,489)




EVOLV TECHNOLOGY
RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA
(In thousands)
(Unaudited)
Three Months Ended
June 30,
Six Months Ended
June 30,
2022 2021 2022 2021
Net income (loss) $ (25,686) $ (22,977) $ (39,487) $ (36,483)
Depreciation & amortization 1,264  611  2,350  1,053 
Stock-based compensation 5,061  1,069  8,988  1,376 
Interest and other expense (income) (332) 3,263  (258) 5,657 
Loss on extinguishment of debt —  11,820  —  11,820 
Change in fair value of derivative liability —  795  —  2,220 
Change in fair value of contingent earn-out liability 569  —  (2,509) — 
Change in fair value of contingently issuable common stock liability 24  —  (1,448) — 
Change in fair value of public warrant liability 143  —  (5,443) — 
Change in fair value of common stock warrant liability —  185  —  921 
Restructuring expenses (13) —  311  — 
Loss on impairment of lease equipment 316  —  412  — 
Other one-time expenses 2,298  —  3,405  — 
Adjusted EBITDA $ (16,356) $ (5,234) $ (33,679) $ (13,436)
EVOLV TECHNOLOGY
RECONCILIATION OF GAAP NET INCOME (LOSS) AND EARNINGS PER SHARE TO ADJUSTED EARNINGS (LOSS) AND ADJUSTED EARNINGS PER SHARE
(In thousands, except share and per share data)
(Unaudited)
Three Months Ended
June 30,
Six Months Ended
June 30,
2022 2021 2022 2021
Net income (loss) $ (25,686) $ (22,977) $ (39,487) $ (36,483)
Stock-based compensation 5,061  1,069  8,988  1,376 
Amortization of capitalized stock-based compensation —  — 
Loss on extinguishment of debt —  11,820  —  11,820 
Change in fair value of derivative liability —  795  —  2,220 
Change in fair value of contingent earn-out liability 569  —  (2,509) — 
Change in fair value of contingently issuable common stock liability 24  —  (1,448) — 
Change in fair value of public warrant liability 143  —  (5,443) — 
Change in fair value of common stock warrant liability —  185  —  921 
Restructuring expenses (13) —  311  — 
Loss on impairment of lease equipment 316  —  412  — 
Other one-time expenses 2,298  —  3,405  — 
Adjusted earnings (loss) $ (17,283) $ (9,108) $ (35,762) $ (20,146)
Weighted average common shares outstanding – basic and diluted 143,552,032  11,922,270  143,220,268  11,186,204 
Adjusted EPS $ (0.12) $ (0.76) $ (0.25) $ (1.80)